Inactivated vaccine · VDDBV0169
Note: 2 additional source trials listed this vaccine in studies of unrelated viruses (e.g. as a comparator, adjunct, or in coadministration trials with other vaccines). Those trials are not shown here.
| NCT ID | Phase | Disease / Condition |
|---|---|---|
| NCT04383574 | Phase 2 | COVID-19 |
| NCT04352608 | Phase 2 | COVID-19 |
| NCT04551547 | Phase 2 | COVID-19 |
| NCT04992182 | Phase 2 | COVID-19 |
| NCT05087368 | Phase 2 | COVID-19 |
| NCT05150496 | Phase 2 | COVID-19 |
| NCT05254236 | Phase 2 | COVID-19 |
| NCT04508075 | Phase 3 | COVID-19 |
| NCT04582344 | Phase 3 | COVID-19 |
| NCT04617483 | Phase 3 | COVID-19 |
| NCT04651790 | Phase 3 | COVID-19 |
| NCT04992260 | Phase 3 | COVID-19 |
| NCT05077176 | Phase 3 | COVID-19 |
| NCT05137418 | Phase 3 | COVID-19 |
| NCT05142319 | Phase 3 | COVID-19 |
| NCT05156632 | Phase 3 | COVID-19 |
| NCT05225285 | Phase 3 | COVID-19 |
| NCT04756830 | Approved | COVID-19 |
| NCT04747821 | Approved | COVID-19 |
| NCT04775069 | Approved | COVID-19 |
| NCT04789356 | Approved | COVID-19 |
| NCT04754698 | Approved | COVID-19 |
| NCT04801888 | Approved | COVID-19 |
| NCT04894227 | Approved | COVID-19 |
| NCT04892459 | Approved | COVID-19 |
| NCT05079217 | Approved | COVID-19 |
| NCT04911790 | Approved | COVID-19 |
| NCT04953325 | Approved | COVID-19 |
| NCT05298800 | Approved | COVID-19 |
| NCT04962308 | Approved | COVID-19 |
| NCT04993365 | Approved | COVID-19 |
| NCT05057169 | Approved | COVID-19 |
| NCT05107557 | Approved | COVID-19 |
| NCT05112913 | Approved | COVID-19 |
| NCT05165732 | Approved | COVID-19 |
| NCT05148949 | Approved | COVID-19 |
| NCT05165966 | Approved | COVID-19 |
| NCT05198336 | Approved | COVID-19 |
| NCT05329038 | Approved | COVID-19 |